In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Allen & Overy reports.
- LSIPR 50 2018: James Flynn—An agent of change in healthcare 16-07-2018
- Will the EPO’s Enlarged Board hear the Broad’s CRISPR case? 13-07-2018
- Searching for variant sequences with pinpoint accuracy 12-07-2018
- The future of precision medicine part 1: challenges and opportunities 13-06-2018
- Regulation and licensing: the CRISPR conundrum continues 04-06-2018
Latest genetics news
A CRISPR patent owned by the Broad Institute of Harvard and MIT is “unpatentable for indefiniteness”, according to an agriculture biotech company.